MHRA says non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden vision deterioration, has been very rarely reported in association with semaglutide used for type 2 diabetes, weight management, and cardiovascular risk reduction. The agency says patients reporting sudden loss of vision, including partial loss, should be urgently referred for ophthalmological examination and that semaglutide should be discontinued if NAION is confirmed.
MHRA also notes that privately prescribed semaglutide may not appear on a patient’s medical history, so clinicians should actively ask about semaglutide use when patients present with these symptoms. That is an important operational point because it shows how postmarketing safety communication increasingly has to account for real-world prescribing pathways, not just standard records.
For pharmacovigilance teams, this is a good example of how a rare but serious event can change clinical advice, referral expectations, and product-information wording. It also reinforces that signal management is not only about identifying patterns, but about translating those patterns into practical risk communication.
0 Comments